{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:21:47Z","timestamp":1778592107981,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K99AA024778"],"award-info":[{"award-number":["K99AA024778"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["Z1A AA000466"],"award-info":[{"award-number":["Z1A AA000466"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002535"],"award-info":[{"award-number":["UL1 TR002535"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Alcohol use disorder (AUD) is a prevalent condition associated with high degree of comorbidity and mortality. Among the few approved pharmacotherapies for AUD, two involve opioid receptor antagonism. Naltrexone and nalmefene are thought to act via opioid receptor blockage to reduce neural response to alcohol and drug-associated cues and consumption, but there have been limited efforts to characterize these effects in humans. In these studies, we sought to test the magnitude of opioid antagonism effects on neural response to monetary rewards in two groups: light drinkers (for the naltrexone study) and heavy drinkers (for the nalmefene study). We conducted double-blind, randomized, crossover pilot studies of reward activation in the brain following acute administration of opioid antagonist and placebo in 11 light and 9 heavy alcohol users. We used a monetary incentive delay task during functional MRI. We found a main effect of cue type on BOLD activation in the nucleus accumbens, demonstrating a neural reward response. The effect of opioid antagonism, relative to placebo, was small and nonsignificant for reward activation in the accumbens for both light and heavy alcohol users. Based on the results of two pilot studies, opioid antagonist medications do not appear to decrease neural activation to monetary rewards in the nucleus accumbens relative to placebo.<\/jats:p>","DOI":"10.1177\/02698811231191707","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T08:15:35Z","timestamp":1690964135000},"page":"937-941","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-6973","authenticated-orcid":false,"given":"Joshua L","family":"Gowin","sequence":"first","affiliation":[{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-8802","authenticated-orcid":false,"given":"Matthew E","family":"Sloan","sequence":"additional","affiliation":[{"name":"Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada"},{"name":"Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Neurosciences and Clinical Translation, Department of Psychiatry, University of Toronto, Toronto, ON, Canada"},{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada"},{"name":"Department of Psychological Clinical Science, University of Toronto Scarborough, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4106-2526","authenticated-orcid":false,"given":"Katelyn T","family":"Kirk-Provencher","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie L","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E","family":"Penner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany L","family":"Stangl","sequence":"additional","affiliation":[{"name":"National Institute on Alcohol Abuse and Alcoholism, Laboratory on Human Psychopharmacology, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nia D","family":"Byrd","sequence":"additional","affiliation":[{"name":"National Institute on Alcohol Abuse and Alcoholism, Laboratory on Human Psychopharmacology, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia E","family":"Swan","sequence":"additional","affiliation":[{"name":"National Institute on Alcohol Abuse and Alcoholism, Laboratory on Human Psychopharmacology, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay A","family":"Ramchandani","sequence":"additional","affiliation":[{"name":"National Institute on Alcohol Abuse and Alcoholism, Laboratory on Human Psychopharmacology, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"bibr1-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"bibr2-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12717"},{"key":"bibr3-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1006\/cbmr.1996.0014"},{"key":"bibr4-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2015.01.002"},{"key":"bibr5-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.06.027"},{"key":"bibr6-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3110"},{"key":"bibr7-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-16-j0002.2001"},{"key":"bibr8-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2013.03.055"},{"key":"bibr9-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.10.020"},{"key":"bibr10-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002902"},{"key":"bibr11-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.65.4.466"},{"key":"bibr12-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12444"},{"key":"bibr13-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3053"},{"key":"bibr14-02698811231191707","doi-asserted-by":"publisher","DOI":"10.3758\/s13415-021-00938-1"},{"key":"bibr15-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.12.029"},{"key":"bibr16-02698811231191707","first-page":"330","volume":"45","author":"Raynor K","year":"1994","journal-title":"Mol Pharmacol"},{"key":"bibr17-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1993.tb02093.x"},{"key":"bibr18-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.195"},{"key":"bibr19-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.74"},{"key":"bibr20-02698811231191707","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1998.00135.x"},{"key":"bibr21-02698811231191707","first-page":"457","volume":"93","author":"Winslow BT","year":"2016","journal-title":"Am Fam Phys"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231191707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811231191707","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231191707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:28Z","timestamp":1777507888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811231191707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/02698811231191707"],"URL":"https:\/\/doi.org\/10.1177\/02698811231191707","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}